Simcere Pharmaceutical Group Limited
SMHGF
$0.6486
-$0.0621-8.74%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.28% | -6.73% | -12.92% | -6.90% | -0.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.28% | -6.73% | -12.92% | -6.90% | -0.24% |
| Cost of Revenue | -20.63% | -15.82% | -12.00% | 1.14% | 16.82% |
| Gross Profit | 5.02% | -3.91% | -13.19% | -9.15% | -4.77% |
| SG&A Expenses | 4.29% | -5.91% | -16.19% | -10.29% | -3.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -69.34% | -24.15% | 17.12% | 18.85% | 20.50% |
| Total Operating Expenses | -8.28% | -13.35% | -19.02% | -10.70% | -1.37% |
| Operating Income | 56.76% | 56.24% | 54.05% | 31.53% | 10.25% |
| Income Before Tax | -2.32% | -106.45% | -133.05% | -106.40% | -8.65% |
| Income Tax Expenses | 207.35% | 98.82% | -39.49% | 299.39% | 166.40% |
| Earnings from Continuing Operations | -9.62% | -108.99% | -133.66% | -107.32% | -15.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -89.00% | -80.90% |
| Net Income | -9.71% | -108.98% | -133.63% | -107.29% | -15.93% |
| EBIT | 56.76% | 56.24% | 54.05% | 31.53% | 10.25% |
| EBITDA | 44.16% | 42.24% | 38.56% | 22.45% | 6.96% |
| EPS Basic | -4.26% | -108.30% | -133.62% | -107.62% | -17.54% |
| Normalized Basic EPS | 51.42% | 53.81% | 55.50% | 36.76% | 17.62% |
| EPS Diluted | -2.67% | -108.58% | -133.84% | -108.14% | -18.58% |
| Normalized Diluted EPS | 51.01% | 53.36% | 55.50% | 36.76% | 17.62% |
| Average Basic Shares Outstanding | -3.66% | -2.62% | -1.57% | -0.84% | -0.10% |
| Average Diluted Shares Outstanding | -3.59% | -2.77% | -1.94% | -1.09% | -0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.07% | -12.25% | -4.07% | -15.17% | 0.23% |